FCMI
LPCN icon

Foresite Capital Management III’s Lipocine LPCN Stock Holding History

Foresite Capital Management III’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-17,802
Closed -$1.35M – 21
2016
Q3 		$1.35M Hold
17,802
– – 0.63% 13
2016
Q2 		$920K Sell
17,802
-5,557
-24% -$861K 0.63% 16
2016
Q1 		$4.03M Buy
23,359
+3,947
+20% +$674K 3.12% 12
2015
Q4 		$4.27M Buy
+19,412
New +$4.07M 3.78% 13

Other funds holding LPCN

RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
CC
Carlson Capital Dallas, Texas $318M AUM 27.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Foresite Capital Management III's LPCN Position: Q4 2016 in Review

Foresite Capital Management III sold out of Lipocine (LPCN) in Q4 2016, closing a stake of 17,802 shares — an estimated $1.35M sold.

Foresite Capital Management III first reported a position in LPCN in Q4 2015 and held it in 4 quarters. The position peaked at $4.27M in Q4 2015. 58 funds tracked by Wall St. Rank hold LPCN as of Q4 2016.

  • Foresite Capital Management III reported no remaining Lipocine position as of Q4 2016 after selling out during the quarter.
  • Foresite Capital Management III sold 17,802 Lipocine shares in Q4 2016, an estimated $1.35M.
  • Foresite Capital Management III first reported a position in Lipocine in Q4 2015 and held it in 4 quarters.
  • Foresite Capital Management III's Lipocine position peaked at $4.27M in Q4 2015.
  • 58 funds tracked by Wall St. Rank held Lipocine as of Q4 2016.

Based on Foresite Capital Management III's 13F filing for Q4 2016, filed 10 Feb 2017.